 This study is an extension study prospective observational study of IDEAL study A Study to Evaluate Efficacy and Safety of Imatinib Glinib 600mgday depending on Early Molecular Response in Newly Diagnosed Patients with Chronic Myeloid Leukemia in Chronic Phase, NCT02204722 to evaluate the duration of treatment response, disease progression, and survival status up to 5 years after the inclusion. 